Clinical safety of long-acting beta2-agonist and inhaled corticosteroid combination therapy in COPD. (Q36714251)

15 August 2017

1 reference

title

Clinical safety of long-acting beta2-agonist and inhaled corticosteroid combination therapy in COPD. (English)

1 reference

chronic obstructive pulmonary disease

15 August 2017

main subject

1 reference

Marc Decramer

1

1 reference

15 August 2017

Gary Ferguson

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

COPD: Journal of Chronic Obstructive Pulmonary Disease

15 August 2017

published in

1 reference

15 August 2017

volume

3

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

163-171

1 reference

An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Contemporary management of chronic obstructive pulmonary disease: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Long-acting inhaled beta 2-agonists for stable COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Effect of beta-adrenergic agonists on mucociliary clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

A comparison of the risk of hospitalizations due to chronicobstructive pulmonary disease in medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Addition of inhaled corticosteroid on combined bronchodilator therapy in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

The TORCH (towards a revolution in COPD health) survival study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Extrapulmonary effects of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Inhaled corticosteroids and hip fracture: a population-based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Impact of long-term inhaled corticosteroid therapy on bone mineral density: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Breathing patterns during vaso-occlusive crisis of sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

The risk of nonvertebral fracture related to inhaled corticosteroid exposure among adults with chronic respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

A population based case-control study of cataract and inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Cardiovascular safety of salmeterol in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Asthma, airway biology, and nasal disorders in AJRCCM 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

Safety of long-acting beta-agonists--an urgent need to clear the air.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600830263

10.1080/15412550600830263

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference